Mr. Kasmiya is a highly esteemed ophthalmologist who has successfully completed specialist training in the field of ophthalmology in some of the most reputable hospitals in the United Kingdom. With years of experience in treating various eye-related conditions, Mr. Kasmiya has established himself as an expert in his field. His skills and knowledge are highly sought-after within the medical community, and he is widely recognized for his contributions to the advancement of ophthalmology. 

Having joined King’s College Hospital as a substantive consultant, he has taken the lead for Diabetic Eye Screening at Bromley in the south London area in partnership with Guy’s and St Thomas’ Hospitals. In addition, he is actively involved in medical and clinical research, contributing to prominent international research related to eye diseases. This has resulted in his appointment as an honorary lecturer at the Imperial College London faculty. He is also a frequent speaker at ophthalmology meetings and serves as an examiner for the King's College University Hospital.

Mr Kasmiya has led retinal services in various trusts, including Chelsea & Westminster Hospital, and has been involved in anti-VEGF injection treatment for Age-related macular degeneration, diabetic retinopathy, laser treatment, and cataract surgeries. With over 21 years of work experience as an eye specialist, including more than two years of quality fellowships, Mr Kasmiya has consolidated his clinical knowledge by performing thousands of cataract surgeries. He is highly skilled in using different types of lenses, including multifocal, toric, and premium IOLs. These surgeries were accomplished to the highest standards with very low complication rates.

Mr. Kasmiya’ passion lies in improving patients' sight and providing professional and truthful advice, alongside the best evidence-based practices in regard to their eye health. His extensive experience and expertise make him a valuable asset in the field of ophthalmology

Useful Links

• maankasmiya.co.uk

Current NHS and/or University Posts

• King's College Hospital

Publications and Research

Mr Kasmiya involved in many world class publications and research:

• STAR Study multi-Centre, factorial, randomised controlled trial to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with established wet age-related macular degeneration (AMD) alongside IVT (Lucentis) to reduce the frequency of injections, King’s College Hospitals NHS , UK,
• CANDEL Study, Multi-Centre, factorial, randomised controlled trial, explore the health and economic impact of a novel therapy for Diabetic Retinopathy (DR) and Diabetic Macular Oedema (DMO) provided by the Noctura 400 Light Mask., UK,
• BRIGHT Study, Multi-Centre, factorial, randomised controlled trial of alternative treatments to inhibit VEGF in Branch retinal vein Occlusion , Comparing Lucentis® (ranibizumub) with laser, steroid injection with respect to the benefits of vascular endothelial growth factor (VEGF) inhibition in maintaining/improving visual acuity in eyes with BRVO Royal Eye Infirmary Plymouth,UK,
• CRYSTAL Study, Multi-Centre, factorial, randomised controlled trial of alternative treatments to inhibit VEGF in Central vein Occlusion , Comparing Lucentis® (ranibizumub) to steroid injection and sham with respect to the benefits of vascular endothelial growth factor (VEGF) inhibition in maintaining/improving visual acuity in eyes with CRVO Royal Eye Infirmary Plymouth,UK,
• MERLOT Study multi-Centre, factorial, randomised controlled trial to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with established wet age-related macular degeneration (AMD) previously treated with anti-VEGF therapy Royal Eye Infirmary Plymouth, UK,
• IVAN Study, Multi-centre, factorial, randomised controlled trial of alternative treatments to inhibit VEGF in age-related choroidal neovascularisation ,Comparing Avastin® (bevacizumab) to Lucentis® (ranibizumub) with respect to the benefits of vascular endothelial growth factor (VEGF) inhibition in maintaining/improving visual acuity in eyes with choroidal neovascularisation (CNV). Wolverhampton Eye Hospital, UK,
• Updated Retinal protocols for AMD, DMO, RVO and Myopic CNVM at Chelsea and Westminster Hospitals, London, UK
• Waqar S, Quinn A, Kasmiya M, the use of post Op. prophylactic antibiotic in Cataract Surgery, The Association for Research in Vision and Ophthalmology, ARVO,
• Murjanah, S,Waqar, Kasmiya M, the Use of Intracameral cefuroxime in Cataract Surgery, British Journal Of Ophthalmology BJO,2010
• Hazarbassanov, W Quinn, Kasmiya M, BJO , efficacy of oral iverectin for treatment of chronic blepharitis in patients tested positive for Demodex Spp, 2011
• Waqar, Kasmiya , J Jacob, Application of the ESCRS recommendations on antibiotics for postoperative endophthalmitis prophylaxis following cataract surgery in the UK,2010
• Waqar S, Quinn A, Kasmiya M, the use of post Op. prophylactic antibiotic in Cataract Surgery, ARVO,2009

Also Mr Kasmiya published articles in well-known National and international Newspapers and websites:

• What you need to know about age-related macular degeneration. – New Year, New You, published and distributed by The Guardian newspaper, 09/01/21
• What you need to know about Diabetic Retinopathy – Good Life, published and distributed by the Daily Mail, 13/02/21

• Cataract Surgery
• Medical Retina
• Intra-Vitreal ANTI-VEGF Injections
• Age Related Macular Degeneration. AMD
• Retinal Vein Occlusion
• Laser Surgery
• Diabetic Eye Disease
• Ozurdex Implants
• Eye Emergency
• Dry eyes
• Chalazion, stye
• Myopia, Refractive errors

• Royal College of Ophthalmologists
• Royal College of Surgeons
• Royal Society of Medicine
• American Academy of Ophthalmology
• European Society of Retinal Specialists
• General Medical Council
• Medical Defence Union